Zacks Investment Research upgraded shares of Celsion (NASDAQ:CLSN) from a sell rating to a hold rating in a research note published on Tuesday, December 19th.
According to Zacks, “Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. “
CLSN has been the subject of several other reports. ValuEngine raised Celsion from a strong sell rating to a sell rating in a research note on Friday, September 1st. Maxim Group raised Celsion from a hold rating to a buy rating and set a $7.00 price objective for the company in a research note on Wednesday, October 4th. Finally, Oppenheimer started coverage on Celsion in a research note on Tuesday, November 21st. They issued an outperform rating and a $9.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. Celsion presently has a consensus rating of Buy and a consensus target price of $11.90.
Shares of Celsion (CLSN) opened at $2.81 on Tuesday. The company has a market capitalization of $45.14, a P/E ratio of -0.48 and a beta of 1.22. Celsion has a 52 week low of $1.24 and a 52 week high of $8.82.
A hedge fund recently raised its stake in Celsion stock. Renaissance Technologies LLC lifted its holdings in shares of Celsion Co. (NASDAQ:CLSN) by 100.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,375,147 shares of the biotechnology company’s stock after acquiring an additional 690,349 shares during the quarter. Renaissance Technologies LLC owned 2.48% of Celsion worth $397,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 3.97% of the company’s stock.
WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/11/celsion-clsn-upgraded-to-hold-at-zacks-investment-research.html.
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Get a free copy of the Zacks research report on Celsion (CLSN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.